Citations

Clear

3485 citation(s) found for "Sy, Sarah".

The Use of Perioperative Cephalexin in Penicillin Allergic Patients in Dermatologic Surgery: An Advisory Statement
Campbell, Elliott H. , Virk, Abinash , Otley, Clark C. , Lessard, Sarah , Otley, Clark, Gonzalez‐Estrada, Alexei

Mayo Clinic

Dermatologic Surgery | August 6, 2025 | Volume: 52 | Issue: 3 | Pages: 221-225

10.1097/dss.0000000000004784 | PMID 40767862 Get It

BACKGROUND Approximately 10% of patients report penicillin allergy. Based on historical guidelines, patients with a penicillin allergy should receive an alternative to cephalexin for prophylaxis in dermatologic surgery. OBJECTIVE To determine, based on evidence, if cephalexin should be used as a first-line prophylactic antibiotic in dermatologic surgery for patients with penicillin allergy. METHODS Systematic review of the literature was performed with defined search terms. RESULTS Less than 5% of those with penicillin allergy labels have a true penicillin allergy. For patients with true, persistent penicillin allergy, there is an overall low cross-reactivity with cephalosporins, especially with cephalosporins that do not share identical R1 side chain. The first-generation cephalosporins, including cephalexin, have a slightly higher risk of cross-reactivity in patients with reported allergy to amino-penicillins (amoxicillin, ampicillin) but not other penicillins. The risk of severe cross-reactivity of cephalosporins in patients with low-risk penicillin allergies is extremely low. Cephalexin has a superior side effect profile and efficacy compared to alternatives. CONCLUSION Cephalexin should be used as the first-line prophylactic antibiotic in dermatologic surgery for patients with documented penicillin allergy, including anaphylaxis. There may be a higher risk of cross-reactivity with cephalexin in patients with a confirmed amino-penicillin allergy.
Long‐Term Outcomes Following Left Atrial Appendage Occlusion in Medicare Beneficiaries: Outcomes From the National Cardiovascular Data Registry
Higgins, Angela Y. , Zimmerman, Sarah , Wang, Yongfei , Faridi, Kamil F. , Price, Matthew J. , Holmes, David R. , Curtis, Jeptha P. , Freeman, James V. , Friedman, Daniel J , Faridi, Kamil F , Price, Matthew J , Reddy, Vivek Y , Holmes, David R , Curtis, Jeptha P , Freeman, James V , Higgins, Angela Y. , Reddy, Vivek Y.

Mayo Clinic

Journal of the American Heart Association | August 6, 2025 | Volume: 14 | Issue: 16 | Pages: No page available

10.1161/jaha.124.039780 | PMID 40767285 Get It

Background Percutaneous left atrial appendage occlusion (LAAO) is an alternative to long‐term anticoagulation for preventing ischemic stroke in patients with atrial fibrillation. There are limited long‐term outcomes data for “real‐world” patients undergoing LAAO. Methods We performed a retrospective cohort study using the National Cardiovascular Data Registry LAAO registry from January 1, 2016, through December 31, 2019. We linked LAAO data to inpatient Medicare fee‐for‐service claims data using probabilistic matching to establish a cohort of patients 65 years and older undergoing LAAO with a WATCHMAN device. The primary outcomes were any stroke and all‐cause mortality. Results A total of 34 975 patients with a mean±SD CHA 2 DS 2 ‐VASc (congestive heart failure, hypertension, age ≥75 years, diabetes, previous stroke or transient ischemic attack, vascular disease, age 65 to 74 years, and sex category) score of 4.7±1.4 were included. The median follow‐up was 2.8 years (interquartile range, 2.2–3.7 years). The cumulative incidence of any stroke was 1.57 per 100 person‐years (95% CI, 1.45–1.70), with a 1‐year and 5‐year any stroke estimate of 1.70% (95% CI, 1.57–1.84%) and 5.70% (95% CI, 5.37–6.05%), respectively. The cumulative incidence of ischemic stroke was 1.36 per 100 person‐years (95% CI, 1.25–1.48), with a 1‐year and 5‐year ischemic stroke estimate of 1.42% (95% CI, 1.30–1.54%) and 5.03% (95% CI, 4.71–5.36%), respectively. The cumulative incidence of death was 10.82 per 100 person‐years (95% CI, 10.49–11.13), with a 5‐year mortality estimate of 44.34% (95% CI, 43.35–45.23%). Conclusions Long‐term stroke rates in a large nationally representative cohort of Medicare patients following LAAO were low and durably consistent during long‐term follow‐up despite a high thromboembolic risk. High mortality rates in this elderly population underscore the importance of incorporating patient values and preferences when considering LAAO.
Wilms Tumor, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology
Benedetti, Daniel J. , Brown, Brandon , Cook, Shelly, Desai, Ami V. , Fair, Douglas , Hiniker, Susan M. , Jasty‐Rao, Rama, Just, Marissa, Kieran, Kathleen , Lin, Chi , MacEwan, Iain, Martínez-Agosto, Julián A. , Mullen, Elizabeth A. , Murphy, Erin S. , Ranalli, Mark , Rhee, Daniel S. , Wickiser, Jonathan E., Yoon, Janet, Zapala, Matthew A. , Sliker, Bailee , Horst, Kelly , Balis, Frank M. , Green, Daniel M. , Armstrong, Amy J. , Aye, Jamie M. , Brown, Brandon Douglas , Brown, Erin G. , Dhillon, Jasreman , Geynisman, Daniel M. , Horst, Kelly K. , Pinto, Navin , Rokitka, Denise A. , Walz, Amy L. , Montgomery, Sarah E.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | August 5, 2025 | Volume: 23 | Issue: 8 | Pages: 319-342

10.6004/jnccn.2025.0037 | PMID 40763792 Get It

The NCCN Clinical Practice Guidelines (NCCN Guidelines) for Wilms Tumor (WT; nephroblastoma) cover strategies for the screening, diagnosis, and treatment of WT, which is the most frequent primary kidney tumor in children. WT can generally be separated into 2 histology types: favorable histology WT and anaplastic WT. Five-year survival is high for children with favorable histology WT who receive appropriate treatment; however, survival rates are much lower for patients who present with higher stage diffuse anaplastic WT. Treatment of WT can range from surgery alone to surgery plus intensive chemotherapy and radiation depending on whether the tumor is unilateral or bilateral, histology, and local stage. The goal of therapy is to maximize cure while minimizing long-term toxicities. The content featured in this issue covers the NCCN panel’s recommendations for overall management of both favorable histology WT and anaplastic WT.
Variables related to locoregional and distant recurrence in esophageal cancer
Fonseca, Stella , RAMOS, Igor Gabriel Silva , Maegawa, Felipe B. , Usón, Pedro Luiz Serrano , Tustumi, Francisco , Fonseca, Sarah , Maegawa, Felipe Antonio Boff , Uson, Pedro L S

Mayo Clinic

ABCD. Arquivos Brasileiros de Cirurgia Digestiva (São Paulo) | August 4, 2025 | Volume: 38 | Issue: No issue available | Pages: No page available

10.1590/0102-67202025000020e1889 | PMID 40767665 Get It

ABSTRACT Background: Esophageal cancer remains one of the most aggressive malignancies of the gastrointestinal tract, with high rates of recurrence and mortality despite curative-intent surgery and adjuvant therapies. Identifying factors associated with recurrence is crucial for improving outcomes and guiding personalized treatment. Aims: The aim of this study was to evaluate pretreatment and treatment-related variables associated with recurrence in patients with esophageal cancer undergoing surgical resection. Methods: This retrospective study analyzed data from patients with stage I–III esophageal carcinoma who underwent esophagectomy between 2000 and 2025, using the Fundação Oncocentro de São Paulo (FOSP) database. Clinical, histological, and treatment-related variables were evaluated. Disease-free survival and recurrence patterns were assessed using Cox proportional hazards models and Fine–Gray subdistribution hazard models. Results: A total of 2,057 patients were included, with a mean follow-up of 36.5 months (±44.8). In the multivariate analysis, advanced tumor stage (stage II: HR 1.68, 95%CI 1.21–2.33; stage III: HR 3.23, 95%CI 2.29–4.56; both p<0.01), location (middle esophagus: HR 1.31, 95%CI 1.11–1.54; p=0.001; upper esophagus: HR 1.54, 95%CI 1.21–1.96; p<0.001), and histological subtype (rare histologies: HR 2.17, 95%CI 1.35–3.49; p=0.001) were associated with worse disease-free survival. Multimodal therapy improved disease-free survival (HR 0.40, 95%CI 0.24–0.66) in stage III tumors. Squamous cell carcinoma was independently associated with locoregional recurrence (SHR 1.52, 95%CI 1.05–2.20; p=0.027). For distant recurrence, squamous cell carcinoma showed a protective effect (SHR 0.52, 95%CI 0.31–0.88; p=0.015), while high tumor grade (grade II: SHR 3.65, 95%CI 1.98–6.72; p<0.001) was associated with an increased risk. Multimodal treatments influenced recurrence patterns but did not independently predict outcomes after adjustment. Conclusions: Tumor stage, location, and histology were strong predictors of disease-free survival after surgery for esophageal cancer. Histological subtypes significantly influenced recurrence patterns. Squamous cell carcinoma was associated with a higher risk of locoregional recurrence but a lower risk of distant metastasis compared to adenocarcinoma. Multimodal therapy demonstrated a protective effect in stage III disease.
Alzheimer's Association Clinical Practice Guideline on the use of blood‐based biomarkers in the diagnostic workup of suspected Alzheimer's disease within specialized care settings
Whitson, Heather E. , Allen, Laura A., Galasko, Douglas, Okrahvi, Hamid R., Paczynski, Madeline , Carrillo, Marı́a C., Edelmayer, Rebecca M. , McAteer, Mary Beth , Pahlke, Sarah , Tampi, Malavika P. , Carrillo, María C. , Palmqvist, Sebastian , Suárez‐Calvet, Marc , Karikari, Thomas K. , Schindler, Suzanne E. , Teunissen, Charlotte E. , Zetterberg, Henrik , Mahinrad, Simin , Kahale, Lara A

Mayo Clinic

Alzheimer's & Dementia | July 29, 2025 | Volume: 21 | Issue: 7 | Pages: No page available

10.1002/alz.70535 | PMID 40729527 Get It

Abstract OBJECTIVE AND SCOPE A panel of clinicians, subject‐matter experts, and guideline methodologists convened by the Alzheimer's Association conducted a systematic review and formulated evidence‐based recommendations for using blood‐based biomarkers (BBMs) in the diagnostic workup of suspected Alzheimer's disease (AD) within specialized care settings. The scope focuses on individuals with objective cognitive impairment, including those with mild cognitive impairment (MCI) or dementia, who are undergoing evaluation by providers trained and experienced in memory disorders, where AD is the suspected underlying etiology. METHODS The panel conducted a systematic review to assess the diagnostic accuracy of BBMs in detecting AD pathology. The BBMs of interest included plasma phosphorylated‐tau (p‐tau) and amyloid‐beta (Aβ) tests measuring the following analytes: p‐tau217, ratio of p‐tau217 to non‐p‐tau217 ×100 (%p‐tau17), p‐tau181, p‐tau231, and ratio of Aβ42 to Aβ40. The reference standard tests included cerebrospinal fluid (CSF) AD biomarkers, amyloid positron emission tomography (PET), or neuropathology. The panel applied the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) approach to assess the certainty of the evidence and the GRADE evidence‐to‐decision (EtD) Framework to develop its recommendations. RECOMMENDATIONS The key recommendations in this Clinical Practice Guideline (CPG) are: (1) BBM tests with ≥90% sensitivity and ≥75% specificity can be used as a triaging test and (2) BBM tests with ≥90% sensitivity and specificity can serve as a substitute for amyloid PET imaging or CSF AD biomarker testing in patients with cognitive impairment presenting to specialized care for memory disorders. The panel cautions users of this guideline that there is significant variability in diagnostic test accuracy and many commercially available BBM tests do not meet these thresholds, especially using a single cutoff. Additionally, these tests do not serve as a substitute for comprehensive clinical evaluation by a healthcare professional and should be used only as part of a full diagnostic workup of patients with cognitive impairment presenting to specialized care settings, and with careful consideration of pretest probability of AD pathology. CONCLUSIONS AND PRACTICAL IMPLICATIONS This CPG provides performance‐based, brand‐agnostic recommendations for the use of BBMs in the diagnostic workup of suspected AD within specialized care settings. By linking recommendations to a systematic review and associated living updates, and using a robust and transparent methodology, the guideline ensures scientific rigor, adaptability, and sustained relevance as evidence evolves. Clinicians are encouraged to stay informed about emerging paradigms—such as biomarker combinations or ratios and multi‐threshold testing—that may further refine the diagnostic accuracy of BBMs as the field evolves.
DNN-Based Noise Reduction Significantly Improves Bimodal Benefit in Background Noise for Cochlear Implant Users
Kolberg, Courtney, Holbert, Sarah O., Bogle, Jamie M. , Saoji, Aniket A.

Mayo Clinic

Journal of Clinical Medicine | July 28, 2025 | Volume: 14 | Issue: 15 | Pages: 5302

10.3390/jcm14155302 | PMID 40806924 Get It

Background/Objectives: Traditional hearing aid noise reduction algorithms offer no additional benefit in noisy situations for bimodal cochlear implant (CI) users with a CI in one ear and a hearing aid (HA) in the other. Recent breakthroughs in deep neural network (DNN)-based noise reduction have improved speech understanding for hearing aid users in noisy environments. These advancements could also boost speech perception in noise for bimodal CI users. This study investigated the effectiveness of DNN-based noise reduction in the HAs used by bimodal CI patients. Methods: Eleven bimodal CI patients, aged 71–89 years old, were fit with a Phonak Audéo Sphere Infinio 90 HA in their non-implanted ear and were provided with a Calm Situation program and Spheric Speech in Loud Noise program that uses DNN-based noise reduction. Sentence recognition scores were measured using AzBio sentences in quiet and in noise with the CI alone, hearing aid alone, and bimodally with both the Calm Situation and DNN HA programs. Results: The DNN program in the hearing aid significantly improved bimodal performance in noise, with sentence recognition scores reaching 79% compared to 60% with Calm Situation (a 19% average benefit, p < 0.001). When compared to the CI-alone condition in multi-talker babble, the DNN HA program offered a 40% bimodal benefit, significantly higher than the 21% score seen with the Calm Situation program. Conclusions: DNN-based noise reduction in HA significantly improves speech understanding in noise for bimodal CI users. Utilization of this technology is a promising option to address patients’ common complaint of speech understanding in noise.
Same-Day Hospital Discharge Is Feasible for a Variety of Urologic Surgeries When Using a Virtual Hybrid Care Hotel
Hampton, Sarah, Perry, Alan G., Kumar, Neal, Hochwald, Alex, Ma, R. , Pak, Raymond W., Petrou, Steven P. , Thiel, David D. , Nazario, Maura, Pathak, Ram A. , Hochwald, Alex P, Ma, Renny, Dora, Chandler , Ma, Renny, Broderick, Gregory A. , Lyon, Timothy D. , Chadha, Ryan

Mayo Clinic

Urology Practice | July 25, 2025 | Volume: 12 | Issue: 6 | Pages: 683-690

10.1097/upj.0000000000000879 | PMID 40709932 Get It

Factors Associated With Diagnosing Psoriatic Arthritis: A Retrospective Study in Northeast Georgia
Faridizad, Romina , Flickinger, Brent A, Rynarzewska, Ania Izabela , Ross, Sarah J. , Ghosh, Aditya , Ghosh, Aditya K , Flickinger, Brent A, Ross, Sarah, Robinson, Shane S.

Mayo Clinic

The Permanente Journal | July 23, 2025 | Volume: 29 | Issue: 3 | Pages: 73-80

10.7812/tpp/25.025 | PMID 40696872 Get It

ERRATUM: Aberrant DNA hypermethylation of SDHC: a novel mechanism of tumor development in Carney triad
Haller, Florian , Moskalev, Evgeny A. , Barthelmeß, Sarah, Otto, Claudia , Rattenberry, Eleanor, Carney, J. Aidan, Hartmann, Arndt, Faucz, Fábio R. , Wiemann, Stefan , Bieg, Matthias , Assié, Guillaume , Bertherat, Jérôme , Schaefer, Inga‐Marie , Maher, Eamonn R. , Ströbel, Philipp , Werner, Martin , Hartmann, Arndt, Stratakis, Constantine A. , Agaimy, Abbas

Mayo Clinic

Endocrine-Related Cancer | July 21, 2025 | Volume: 32 | Issue: 7 | Pages: No page available

10.1530/erc-14-0254e | PMID 40686492 Get It